is also excited by the possibilities these new insights into EBV’s role raise for developing new treatments. “The virus is smart,” he says. “It hides in B-cells, so targeting it using a ...

Without EBNA1, EBV cannot live in B cells, and MS patients have higher levels of antibodies towards EBNA1. But EBV makes over 80 different proteins during its life cycle. In our latest work ...

EBV is so prevalent that an estimated 90 percent of individuals will be infected by the time they are 20. Once inside the ...

Although it is unclear what can trigger a reactivation of EBV, it may be due to an activation of B cells — a type of white blood cells in your immune system — in response to an unrelated ...

A newly identified condition, called “post-vaccination syndrome” (PVS), appears to be linked to mRNA Covid vaccines.

In animal studies, a similar vaccine candidate from ModeX generated neutralising antibodies in mice, ferrets, and nonhuman primates that inhibited EBV entry into both B cells and epithelial cells ...

(Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV ... range of hematological malignancies and B-cell driven autoimmune diseases.

(Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV ... range of hematological malignancies and B-cell driven autoimmune diseases.